The following information is disclosed in accordance with AIM Rule 26.
Last updated 12th March 2021.
|Business Description||Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.
Our mission is to be a world leader in rare and orphan diseases.
Click here to find out more about us.
|Incorporation & Registered Office||Country of Incorporation:
England & WalesMain country of operation:
IrelandCompany registration number:
196 High Road
London N22 8HH
|Company Directors||Ray Stafford (Non-executive Chairman)
Joseph Wiley (Chief Executive Officer)
George Hampton (Non-executive Director)
Alain Munoz (Non-executive Director)
Donald Stern (Non-executive Director)
Patrick Vink (Non-executive Director)
Stephen Wills (Non-executive Director)View directors’ biographies
|Corporate Governance||The Quoted Companies Alliance (QCA) has published a corporate governance code for small and medium sized quoted companies, which includes a standard of minimum best practice for AIM companies and recommendations for reporting corporate governance matters (QCA Code). The QCA code is constructed around ten broad principles which the Company has chosen to apply to ensure good governance practices are in place.
Information on Corporate Governance can be found here.
|UK Takeover code||The Company is subject to the UK City Code on Takeovers and Mergers.|
|Annual and Half Yearly Reports & Accounts||Annual and Half Yearly Reports & Accounts can be found here.
|RNS Announcements||RNS announcements can be found here.|
|Details of Restrictions on the Transfer of Securities||There are no restrictions on the transfer of ordinary shares.|
|Details of any other Exchanges or Trading Platform||The shares of the Company are traded on the NASDAQ Global Select Market and the AIM market operated by the London Stock Exchange.|
|Shares & Significant Shareholders||On August 31 2021 the issued share capital comprised 316,496,087 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company at August 31, 2021 was 316,496,087.
This figure of 316,496,087 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.
The identity and shareholdings of the Company’s significant shareholder can be found here.
|Shares not in public hands||Pursuant to the AIM rules, and insofar as the Company is aware, as at 29 June 2021, 28.39% of the Company’s issued share capital is not in public hands.|